[U.S. Stock Market Movement] American Tower surged on October 9: SpaceX purchased spectrum + communication tower leasing
Bitget异动解读2026/10/09 13:35US Tower Companies Surge on October 9: Analysis
Keywords: SpaceX spectrum acquisition, communications tower leasing
1. On October 8, SpaceX agreed to acquire nationwide low-frequency spectrum for approximately $8 billion, aiming to enhance satellite-to-phone services. The relevant spectrum can improve signal penetration through obstacles and retains the potential for building ground networks.
2. On October 8, the related transaction was seen as potentially boosting ground infrastructure development. If SpaceX expands its communications coverage, it may require more ground networks and communications tower facilities, allowing tower operators to earn income from new tenants.
3. On October 9, US tower companies rose as much as 6.81% in pre-market trading. The company owns nearly 149,000 communications sites and mainly leases site space to wireless service providers and other clients. The SpaceX spectrum deal is directly linked to its communications infrastructure business.
(Disclaimer: This content is summarized and generated using AI technology based on publicly available information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
INE crude oil main contract falls below 730 yuan/barrel, down 1.55% intraday
The main contract of Chinese INE crude oil futures has just broken through the 730.0 yuan/barrel level, with the latest quote at 729.8 yuan/barrel, down 1.55% on the day. The main contract of US unleaded gasoline futures has just broken through the $3.2800/gallon level, with the latest quote at $3.2791/gallon, down 1.11% on the day.
US Stock Market Movement: Mirum surges on October 9 as AZURE-1 meets criteria and receives FDA approval